AU2001255796A1 - (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors - Google Patents

(2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors

Info

Publication number
AU2001255796A1
AU2001255796A1 AU2001255796A AU5579601A AU2001255796A1 AU 2001255796 A1 AU2001255796 A1 AU 2001255796A1 AU 2001255796 A AU2001255796 A AU 2001255796A AU 5579601 A AU5579601 A AU 5579601A AU 2001255796 A1 AU2001255796 A1 AU 2001255796A1
Authority
AU
Australia
Prior art keywords
ylidenyl
oxindol
acetic acid
acid derivatives
protein kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255796A
Inventor
Chung-Chen Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of AU2001255796A1 publication Critical patent/AU2001255796A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
AU2001255796A 2000-05-02 2001-05-02 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors Abandoned AU2001255796A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20117300P 2000-05-02 2000-05-02
US60201173 2000-05-02
PCT/US2001/014230 WO2001083450A2 (en) 2000-05-02 2001-05-02 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2001255796A1 true AU2001255796A1 (en) 2001-11-12

Family

ID=22744765

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255796A Abandoned AU2001255796A1 (en) 2000-05-02 2001-05-02 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors

Country Status (7)

Country Link
US (3) US20020028828A1 (en)
EP (1) EP1299355A2 (en)
JP (1) JP2003531895A (en)
AU (1) AU2001255796A1 (en)
CA (1) CA2407799A1 (en)
MX (1) MXPA02010759A (en)
WO (1) WO2001083450A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987113B2 (en) 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
WO2003000251A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel idolinones and uses thereof
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
MXPA06004438A (en) 2003-10-24 2006-06-20 Schering Ag Indolinone derivatives and their use in treating disease-states such as cancer.
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (en) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 Naphthaline amide derivative serving as protein kinase inhibitor and histone deacetylase inhibitor and preparation method and application thereof
EP2654799B1 (en) 2010-12-23 2017-11-08 Nektar Therapeutics Polymer-sunitinib conjugates
JP6009457B2 (en) 2010-12-23 2016-10-19 ネクター セラピューティクス Polymer-desethylsunitinib conjugate
IN2014DN06869A (en) * 2012-01-26 2015-05-22 Angion Biomedica Corp
DK3466934T3 (en) 2016-05-31 2024-04-15 Taiho Pharmaceutical Co Ltd SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
US10889555B2 (en) 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8816944D0 (en) * 1988-07-15 1988-08-17 Sobio Lab Compounds
IL97872A (en) 1990-04-16 1996-07-23 Rhone Poulenc Rorer Int Pharmaceutical compositions containing styryl-substituted monocylic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase and a compounds of this type
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5418245A (en) * 1990-04-16 1995-05-23 Rhone-Poulenc Rorer International (Holdings) Inc. Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit EGF receptor tyrosine kinase
US5121014A (en) 1991-03-05 1992-06-09 Vlsi Technology, Inc. CMOS delay circuit with controllable delay
US5656655A (en) * 1994-03-17 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
US5451494A (en) * 1994-04-28 1995-09-19 Eastman Kodak Company Photographic elements containing acyl substituted oxonol dyes
US6316635B1 (en) * 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP0788890A1 (en) 1996-02-06 1997-08-13 Agfa-Gevaert N.V. Dyes and dye-donor elements for thermal dye transfer recording
WO1998045708A1 (en) 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US6316429B1 (en) * 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6486185B1 (en) * 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US20040067531A1 (en) 1997-08-20 2004-04-08 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
WO2000008202A2 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
JP2002507598A (en) 1998-03-26 2002-03-12 スージェン・インコーポレーテッド A family of heterocyclic compounds for regulating tyrosine protein kinase
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
HUP0103617A2 (en) * 1998-05-29 2002-02-28 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors, pharmaceutical compositions containing the compounds and their use
WO1999065875A1 (en) 1998-06-17 1999-12-23 Geron Corporation Telomerase inhibitors

Also Published As

Publication number Publication date
WO2001083450A2 (en) 2001-11-08
JP2003531895A (en) 2003-10-28
US20020028828A1 (en) 2002-03-07
EP1299355A2 (en) 2003-04-09
US20030216462A1 (en) 2003-11-20
WO2001083450A3 (en) 2002-04-11
US7214700B2 (en) 2007-05-08
US20040039196A1 (en) 2004-02-26
MXPA02010759A (en) 2004-07-30
CA2407799A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
AU2728201A (en) 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
IL154016A0 (en) Pyrazole derivatives and their use as protein kinase inhibitors
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2563900A (en) Quinoline derivatives as tyrosine kinase inhibitors
AU2002213485A1 (en) Inhibitors of protein kinases
AU2001232799A1 (en) Protein c derivatives
AU2001251063A1 (en) 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AU2002231166A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AU2002234047A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AU2002334355A1 (en) Protein tyrosine kinase inhibitors
AU2001269503A1 (en) Amino alcohol derivatives
IL151045A0 (en) 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2001265111A1 (en) Benzenedicarboxylic acid derivatives
AU2001278986A1 (en) 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors
AU2001247882A1 (en) Tricyclic protein kinase inhibitors
AU2001255796A1 (en) (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
AU2576501A (en) Protein kinase inhibitors
AU2001280167A1 (en) Novel propenohydroxamic acid derivatives
AU2001292019A1 (en) Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease
AU2003205558A1 (en) Thioibotenic acid and derivatives thereof
AU1189201A (en) Therapeutic compositions including protein kinase c inhibitors
AU6038601A (en) Amino acid derivatives and their use as medicines
AU2001235437A1 (en) Isothiazolecarboxylic acid derivatives and their use as microbicides